Catherine Skari

CLINICAL NEWS | FDA Approves Luspatercept for First-line Treatment of Anemia in Lower-Risk MDS

The approval was based on interim results from the pivotal phase 3 COMMANDS trial (ClinicalTrials.gov Identifier: NCT03682536) that evaluated the efficacy…

Read More »

TIF European Health Policy Webinar Series | 21 September 2023

Designed for patients and their families, these webinars aim to foster national advocacy for the improvement of service delivery. The…

Read More »

PUBLICATIONS | Nutrition Guidelines in Thalassemia & PKD

Nutrition holds a significant position in the lives of individuals afflicted with thalassaemia and other hereditary anaemias. As part of…

Read More »

IN THE SPOTLIGHT | Explore Our Latest Work in the TIF Newsletter, August Edition

The remarkable collaborations and activities carried out in the past two months have been truly invigorating, and we eagerly anticipate…

Read More »

Pregnancy-related Thromboembolism in Women with Sickle Cell Disease: An Analysis of National Medicaid Data

Pregnancy and sickle cell disease (SCD) both individually carry a risk of thromboembolism (TE). Pregnancy in people with SCD may…

Read More »

Speckle Tracking Echocardiography and Β-Thalassemia Major: A Systematic Review

Heart disease is among the primary causes of morbidity and mortality in β-thalassemia major (β-TM). Conventional echocardiography has failed to…

Read More »

SLN124, a GalNAc Conjugated 19‐mer siRNA Targeting tmprss6, Reduces Plasma Iron and Increases Hepcidin Levels of Healthy Volunteers

SLN124, an N-acetylgalactosamine conjugated 19-mer short interfering RNA, is being developed to treat iron-loading anemias (including beta-thalassemia and myelodysplastic syndromes)…

Read More »

The Hidden Dangers of Sickle Cell Trait: Unraveling the Risk for Complications

Worldwide, it is estimated that there are 300 million people with sickle cell trait and one-third of this number are…

Read More »